A Quantum Chemistry Platform Called Qrunch Is Introduced by Kvantify to Unlock Molecular Innovation. A Danish company called Kvantify has released software for quantum computers that uses transformative chemistry.
The flagship product, Kvantify Qrunch, was formally introduced on November 19, 2025, by the Danish business Kvantify, a leader in quantum computing software. This new technology is specifically made to run calculations related to quantum chemistry on real quantum computers. At SC25 in St. Louis, the program made its debut. Kvantify Qrunch seeks to be a pivotal point in mediating the quantum computing-based transformation of molecular discovery.
Particularly in domains like drug discovery and materials science, Qrunch’s primary goal is to close the substantial gap between increasingly potent but still undeveloped quantum hardware and real-world, commercial applications. By combining quantum and classical computer techniques, Qrunch could revolutionize molecular discovery and make it easier to develop novel medications, materials, and energy.
You can also read IonQ Leads 2000% Record in Deloitte Technology Fast 500 2025
Addressing Fundamental Barriers to Enterprise Adoption
Chemical simulations are an important part of innovation in the biotech and pharmaceutical industries; however, there are three main obstacles to the enterprise’s use of quantum computing for these applications:
- Researchers who are not quantum experts have limited access.
- Not being scalable enough to handle the sizes of real-world problems.
- Prohibitive ratios of cost to value.
Kvantify Qrunch meets these challenges by providing enterprise-grade quantum technology tailored to computational chemistry operations. The platform’s user-friendly, domain-specific interface abstracts complicated quantum operations. Without requiring in-depth knowledge of quantum computing, this allows domain scientists like chemists and materials researchers to create and implement quantum algorithms. Professor Nikolaj Zinner, CSO of Kvantify, claims that the program was made with accessibility in mind, enabling those who are not quantum experts to make use of this potent technology.
When compared to direct hardware programming, this method significantly shortens the workflow development time, freeing computational chemists to concentrate on addressing scientific problems instead of handling qubit topological constraints or quantum gate sequences.
Technical Capabilities and Scalability Breakthroughs
Its domain-specific methodology, which enables full-chip utilization of quantum technology, is a key difference for Kvantify Qrunch. Nikolaj Zinner clarified that Qrunch’s chemistry-specific techniques allow for effective execution over whole processor architectures, whereas traditional quantum software normally only accesses 10–30% of the available qubits.
Validated by molecular simulations using up to 80 qubits on existing quantum processors, this efficiency shows a notable 3–4x increase in problem-size capacity over conventional methods. The pharmaceutical and materials research sectors can benefit from these capabilities by reducing project deadlines, expanding the breadth of tractable molecular systems, and modelling larger, commercially relevant compounds. Additionally, Qrunch is compatible with all of the gate-based quantum computers available today, including those that can be accessed via Amazon Web Services’ (AWS) quantum computing service, Amazon Braket.
You can also read Argonne-Backed Teams Named ACM Gordon Bell Prize Finalists
Strategic Partnership with IQM Quantum Computers
Qrunch, founded with IQM Quantum Computers, is embedded in the European quantum ecosystem. Qrunch’s integrated hardware comes from IQM, a Finnish-German superconducting quantum computing leader. This collaboration makes Kvantify and IQM European champions, strengthening the quantum ecosystem through hardware-software synergies.
“Kvantify Qrunch offers performance quantum software, which is essential for commercializing quantum computing,” said Jan Goetz, co-founder and co-CEO of IQM Quantum Computers.
Novonesis Leads Commercial Testing
The well-known biotech company Novonesis was one of the first to test Qrunch. With Qrunch, Novonesis hopes to shorten project durations and simulate bigger molecules that are pertinent to business uses. Their main objective is to increase the efficiency of already available enzyme products and study the behavior of enzymes during catalysis, which might result in a greater understanding of basic biological processes. “This capability will allow them to gain insights that can improve the efficiency of their existing enzyme products,” confirmed Lars Olsen, Senior Department Manager at Novonesis.
The launch’s sponsor, Kvantify, a Danish firm founded in 2022, employs 49 people at the moment. The business focuses on the life science sector, especially in the early phases of drug discovery, and specializes in software creation for both quantum and traditional computers.
In computational chemistry, Kvantify Qrunch presents quantum computing as a tool that actively pushes the boundaries of problems that can be solved. In order to revolutionize molecular research, it is imperative that quantum chemistry computations be made accessible, scalable, and economical.
You can also read NASA & JPL Are Advancing Quantum Sensors for Space Science
